LENSAR Inc
NASDAQ:LNSR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (19.2), the stock would be worth $-53.47 (1 083% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2 | $5.44 |
0%
|
| Industry Average | 19.2 | $-53.47 |
-1 083%
|
| Country Average | 19.6 | $-54.51 |
-1 102%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$52.7m
|
/ |
Jan 2026
$-24.6m
|
= |
|
|
$52.7m
|
/ |
Dec 2026
$306k
|
= |
|
|
$52.7m
|
/ |
Dec 2027
$6.7m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
LENSAR Inc
NASDAQ:LNSR
|
65.2m USD | -2 | -1.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
159.2B USD | 19 | 25.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.7B USD | 56.1 | 60.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126B USD | 24 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.8B USD | 18.8 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
96.2B USD | 26.4 | 33.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
41.6B EUR | 15.6 | 19.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.3B USD | 26.3 | 44.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.1B USD | 34 | 43.5 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.3B USD | 16.9 | 25.2 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.5B USD | 13.6 | 15.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
LENSAR Inc
Glance View
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 110 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The company is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.
